Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

AstraZeneca shots have good risk-benefit profile for over 60s, says EMA official

Published 13/06/2021, 09:39
Updated 13/06/2021, 21:05
© Reuters. FILE PHOTO: Syringes with AstraZeneca coronavirus disease (COVID-19) vaccines are prepared in Fasano Italy, April 13, 2021. REUTERS/Alessandro Garofalo

© Reuters. FILE PHOTO: Syringes with AstraZeneca coronavirus disease (COVID-19) vaccines are prepared in Fasano Italy, April 13, 2021. REUTERS/Alessandro Garofalo

MILAN (Reuters) -The head of the EU drug regulator's COVID-19 task force said on Sunday that AstraZeneca (NASDAQ:AZN)'s coronavirus vaccine had a favourable risk-benefit profile for all age groups and particularly for those aged over 60.

Italian newspaper La Stampa earlier quoted European Medicines Agency (EMA) task force chief Marco Cavaleri as saying countries should avoid giving the vaccine to people aged over 60 in addition to younger age groups, amid fears over very rare blood clotting and as alternative vaccines become available.

"Unfortunately my words have not been interpreted correctly in a recent interview with La Stampa," Cavaleri said in a statement to Reuters. The AstraZeneca shot "maintains a favourable benefit risk profile in all ages but particularly in the elderly above 60," he said.

The EMA's position is that the AstraZeneca shot is safe and can be used for all age groups over 18. However several European Union member states have stopped administering it to people below a certain age, usually ranging from 50 to 65, restricting its use to older people, due to very rare cases of blood clotting, mainly among young people.

On Sunday evening, La Stampa changed the headline on its article online and added a clarification with Cavaleri's later comments to its article. La Stampa editor Massimo Giannini said he had no further comment.

Earlier this week the Italian government said it would restrict the use of the AstraZeneca vaccine to people aged over 60, after a teenager who had received the shot died from a rare form of blood clotting.

© Reuters. FILE PHOTO: Syringes with AstraZeneca coronavirus disease (COVID-19) vaccines are prepared in Fasano Italy, April 13, 2021. REUTERS/Alessandro Garofalo

Italian Health Minister Roberto Speranza told reporters on Sunday that Italy will continue to use the AstraZeneca vaccine on the over 60s, including those who have not received a first shot.

Like many European countries, Italy briefly halted AstraZeneca inoculations in March over concerns about the very rare blood clotting problems. It resumed them the following month with the recommendation that the product be "preferably" used for people over the age of 60, after the EMA said its benefits outweighed any risks.

Latest comments

every I read EU the story is dead for me
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.